A new spin-out company from the University of Cambridge and Addenbrooke's Hospital, XO1 Ltd, has raised $11 million in funding to develop a new anticoagulant drug which has the potential to save millions of lives by preventing ...
Jun 17, 2013
0
0
Shares of Elan Corp. PLC jumped Friday after Royalty Pharma once again raised its offer to buy the Irish drugmaker in an increasingly bitter takeover fight.
Jun 7, 2013
0
0
Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the ...
Jun 4, 2013
0
0
In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and ...
Jun 4, 2013
0
0
Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin ...
May 27, 2013
1
0
Sleeping sickness kills tens of thousands of people in Africa each year. Current chemotherapies are subject to various limitations, including resistance. Rhodesain, an enzyme of the parasites that cause this illness (human ...
May 17, 2013
1
0
Stanford University School of Medicine scientists have created a mouse model of muscular dystrophy in which degenerating muscle tissue gives off visible light. The observed luminescence occurs only in damaged muscle tissue ...
Apr 24, 2013
0
0
Bioengineered rat kidneys developed by Massachusetts General Hospital (MGH) investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals. In their report, receiving ...
Apr 14, 2013
4
0
The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American ...
Apr 9, 2013
0
0
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This ...
Apr 9, 2013
0
0
